APM
BHVN

Avidity Partners Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Avidity Partners Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,231,000
Closed -$146M – 103
2022
Q1 		$146M Buy
1,231,000
+91,000
+8% +$11.3M 3.24% 10
2021
Q4 		$157M Buy
1,140,000
+205,800
+22% +$26.2M 3.33% 6
2021
Q3 		$130M Buy
934,200
+51,700
+6% +$6.46M 3.31% 9
2021
Q2 		$85.7M Sell
882,500
-167,300
-16% -$13.6M 2.32% 10
2021
Q1 		$71.8M Buy
1,049,800
+558,000
+113% +$45.1M 2% 15
2020
Q4 		$42.2M Sell
491,800
-792,400
-62% -$67.1M 1.42% 24
2020
Q3 		$83.5M Buy
1,284,200
+179,700
+16% +$11.8M 4.5% 7
2020
Q2 		$80.8M Buy
1,104,500
+564,500
+105% +$30M 5.18% 3
2020
Q1 		$18.4M Buy
+540,000
New +$24.7M 2.63% 13

Other funds holding BHVN

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $15.3B AUM 50.95% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.37B AUM 63.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return